The inhibition of intestinal LCFA, glucose and fructose transporters is a promising target regarding the prevention and treatment of not only metabolic disorders such as T2DM, but also other diseases which are correlated with high blood concentration of these food components. The gene discussed is SLC2A5; the disease is metabolic disease.